Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) Versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial) .
Sponsor: PharmaMar .
View of NCT02566993 on 2016_12_25
ClinicalTrials Identifier: NCT02566993
Updated: 2016_12_25 .
Health Authority: United States: Food and Drug Administration .
Lebanon: Ministry of Public Health .
Hungary: National Institute of Pharmacy .
Canada: Health Canada .
Czech Republic: State Institute for Drug Control .
Austria: Austrian Federal Office for Safety in Health Care .
Belgium: Federal Agency for Medicines and Health Products, FAMHP .
Brazil: National Health Surveillance Agency .
Portugal: INFARMED, National Authority of Medicines and Health Products, IP .
Spain: Agencia Española de Medicamentos y Productos Sanitarios .
Greece: National Organization of Medicines .
United Kingdom: Medicines and Healthcare Products Regulatory Agency .
Germany: Federal Institute for Drugs and Medical Devices .
Italy: The Italian Medicines Agency .
Bulgaria: Bulgarian Drug Agency .